DA32 Life Science Tech Acquisition
| General Information | |
| Business: | We intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. We are offering Class A ordinary shares. (This is NOT a unit offering; most blank-check or SPAC IPOs are unit offerings.) Our CEO is Steven Kafka, Ph.D., a managing partner at Section 32, a venture capital fund. We are sponsored by Deerfield Management, ARCH Venture Partners and Section 32. (Note: DA32 Life Science Tech Acquisition priced its SPAC IPO on July 27, 2021, in line with the terms in its prospectus: 20 million Class A ordinary shares at $10 each to raise $200 million.) |
| Industry: | BLANK CHECKS |
| Employees: | 0 |
| Founded: | 2021 |
| Contact Information | |
| Address | 345 Park Avenue South, 12th Floor New York, NY 10010, US |
| Phone Number | (212) 551-1600 |
| Web Address | |
| View Prospectus: | DA32 Life Science Tech Acquisition |
| Financial Information | |
| Market Cap | $256.5mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $0 mil (last 12 months) |
| IPO Profile | |
| Symbol | DALS |
| Exchange | NASDAQ |
| Shares (millions): | 20.0 |
| Price range | $10.00 - $10.00 |
| Est. $ Volume | $200.0 mil |
| Manager / Joint Managers | J.P. Morgan/ Cowen and Company |
| CO-Managers | - |
| Expected To Trade: | 7/28/2021 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |